8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 27, 2026·SEC
Intellia Therapeutics, Inc.(NTLA)Earnings, Financials & Key Ratios
NTLA•NASDAQ
Price updated Jun 19, 2026
AboutIntellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$68M+16.9%
- EBITDA-$425M+18.9%
- Net Income-$413M+20.5%
- EPS (Diluted)-3.81+27.4%
- Gross Margin76.47%-7.0%
- EBITDA Margin-628.14%+30.6%
- Operating Margin-651.67%+29.4%
- Net Margin-609.85%+32.0%
- ROE-53.48%+1.0%
NTLA Key Insights
Intellia Therapeutics, Inc. (NTLA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 25.2% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NTLA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NTLA Price & Volume
Intellia Therapeutics, Inc. (NTLA) stock price & volume — 10-year historical chart
Loading chart...
NTLA Growth Metrics
Intellia Therapeutics, Inc. (NTLA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.32%
5 Years3.13%
3 Years9.09%
TTM45.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.31%
Return on Capital
10 Years-33.61%
5 Years-40.29%
3 Years-45.2%
Last Year-48.5%
NTLA Recent Earnings
Intellia Therapeutics, Inc. (NTLA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.81+12.0%
$0.92
Rev
$15M+9.0%
$14M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.83+16.2%
$0.99
Rev
$23M+92.1%
$12M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.92+9.8%
$1.02
Rev
$14M+13.2%
$12M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.99+3.9%
$1.03
Rev
$14M+1.3%
$14M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.81vs $0.92+12.0% | $15Mvs $14M+9.0% |
| Q1 2026 | Feb 26, 2026 | $0.83vs $0.99+16.2% | $23Mvs $12M+92.1% |
| Q4 2025 | Nov 6, 2025 | $0.92vs $1.02+9.8% | $14Mvs $12M+13.2% |
| Q3 2025 | Aug 7, 2025 | $0.99vs $1.03+3.9% | $14Mvs $14M+1.3% |
Based on last 12 quarters of dataView full earnings history →
NTLA Peer Comparison
Intellia Therapeutics, Inc. (NTLA) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 ARCT | 214.03M | 7.53 | -3.14 | -51.43% | -173.47% | -36.55% | 0.12 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare NTLA vs Peers
Intellia Therapeutics, Inc. (NTLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NTLA Income Statement
Intellia Therapeutics, Inc. (NTLA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 26.12M | 30.43M | 43.1M | 57.99M | 33.05M | 52.12M | 36.27M | 57.88M | 67.67M | 66.09M |
Revenue Growth % | 58.49% | 16.53% | 41.63% | 34.55% | -43.01% | 57.69% | -30.4% | 59.55% | 16.92% | 45.04% |
Cost of Goods Sold | 67.65M | 89.11M | 108.41M | 150.41M | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M | 87.17M |
COGS % of Revenue | 259.02% | 292.81% | 251.52% | 259.35% | 20.85% | 14.53% | 24.74% | 17.77% | 23.53% | - |
Gross Profit | -41.53M▲ 0% | -58.68M▼ 41.3% | -65.31M▼ 11.3% | -92.41M▼ 41.5% | 26.16M▲ 128.3% | 44.55M▲ 70.3% | 27.3M▼ 38.7% | 47.59M▲ 74.3% | 51.75M▲ 8.7% | -21.07M▲ 0% |
Gross Margin % | -159.02% | -192.81% | -151.52% | -159.35% | 79.15% | 85.47% | 75.26% | 82.23% | 76.47% | -31.89% |
Gross Profit Growth % | -170.36% | -41.3% | -11.3% | -41.5% | 128.31% | 70.28% | -38.72% | 74.34% | 8.73% | - |
Operating Expenses | 95.67M | 121.3M | 41.06M | 44.17M | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M | 399.64M |
OpEx % of Revenue | 366.32% | 398.58% | 95.26% | 76.16% | 889.52% | 964.51% | 1495.77% | 1005.33% | 728.14% | - |
Selling, General & Admin | 28.02M | 32.19M | 41.06M | 44.17M | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M | 141.43M |
SG&A % of Revenue | 107.31% | 105.77% | 95.26% | 76.16% | 215.1% | 173.26% | 321.15% | 217.41% | 177.03% | - |
Research & Development | 67.65M | 89.11M | 108.41M | 150.41M | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M | 361.17M |
R&D % of Revenue | 259.02% | 292.81% | 251.52% | 259.35% | 695.27% | 805.78% | 1199.36% | 805.69% | 574.63% | - |
Other Operating Expenses | 0 | 0 | -108.41M | -150.41M | -6.89M | -7.57M | -8.98M | -10.29M | -15.92M | -3M |
Operating Income | -69.56M▲ 0% | -90.87M▼ 30.6% | -106.37M▼ 17.1% | -136.58M▼ 28.4% | -267.85M▼ 96.1% | -458.16M▼ 71.1% | -515.29M▼ 12.5% | -534.26M▼ 3.7% | -440.99M▲ 17.5% | -420.71M▲ 0% |
Operating Margin % | -266.32% | -298.58% | -246.78% | -235.51% | -810.37% | -879.04% | -1420.51% | -923.1% | -651.67% | -636.56% |
Operating Income Growth % | -116.28% | -30.64% | -17.06% | -28.41% | -96.11% | -71.05% | -12.47% | -3.68% | 17.46% | - |
EBITDA | -66.56M | -86.41M | -100.78M | -130.27M | -260.96M | -450.59M | -506.31M | -523.98M | -425.07M | -410.73M |
EBITDA Margin % | -254.86% | -283.91% | -233.81% | -224.63% | -789.52% | -864.51% | -1395.77% | -905.33% | -628.14% | -621.45% |
EBITDA Growth % | -114.33% | -29.81% | -16.64% | -29.26% | -100.32% | -72.67% | -12.37% | -3.49% | 18.88% | 22.62% |
D&A (Non-Cash Add-back) | 2.99M | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M | 9.99M |
EBIT | -69.56M | -90.87M | -106.37M | -136.58M | -267.85M | -458.16M | -515.29M | -534.26M | -412.69M | -407.64M |
Net Interest Income | 2.01M | 5.53M | 6.83M | 2.35M | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M | 25.8M |
Interest Income | 2.01M | 5.53M | 6.83M | 2.35M | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M | 25.8M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 2.01M | 5.53M | 6.83M | 2.35M | -42K | -16.02M | 34.1M | 15.24M | 28.3M | 26.12M |
Pretax Income | -67.54M▲ 0% | -85.34M▼ 26.4% | -99.53M▼ 16.6% | -134.23M▼ 34.9% | -267.89M▼ 99.6% | -474.19M▼ 77.0% | -481.19M▼ 1.5% | -519.02M▼ 7.9% | -412.69M▲ 20.5% | -394.6M▲ 0% |
Pretax Margin % | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% | -609.85% | -597.04% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -67.54M▲ 0% | -85.34M▼ 26.4% | -99.53M▼ 16.6% | -134.23M▼ 34.9% | -267.89M▼ 99.6% | -474.19M▼ 77.0% | -481.19M▼ 1.5% | -519.02M▼ 7.9% | -412.69M▲ 20.5% | -394.6M▲ 0% |
Net Margin % | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% | -609.85% | -597.04% |
Net Income Growth % | -113.51% | -26.35% | -16.63% | -34.86% | -99.58% | -77.01% | -1.48% | -7.86% | 20.49% | 24.97% |
Net Income (Continuing) | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -412.69M | -394.6M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.88▲ 0% | -1.98▼ 5.3% | -1.96▲ 1.0% | -2.40▼ 22.4% | -3.78▼ 57.5% | -6.16▼ 63.0% | -5.42▲ 12.0% | -5.25▲ 3.1% | -3.81▲ 27.4% | -3.33▲ 0% |
EPS Growth % | -106.59% | -5.32% | 1.01% | -22.45% | -57.5% | -62.96% | 12.01% | 3.14% | 27.43% | 32.31% |
EPS (Basic) | -1.88 | -1.98 | -1.96 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | - |
Diluted Shares Outstanding | 36.01M | 43.07M | 47.25M | 55.99M | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M | 118.49M |
Basic Shares Outstanding | 36.01M | 43.07M | 47.25M | 55.99M | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M | 118.49M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NTLA Balance Sheet
Intellia Therapeutics, Inc. (NTLA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 354.83M | 324.98M | 289.48M | 616.52M | 769.3M | 1.22B | 998.33M | 639.86M | 527.71M | 466.45M |
Cash & Short-Term Investments | 340.68M | 314.06M | 279.73M | 597.37M | 748.69M | 1.19B | 912.22M | 601.51M | 449.88M | 375.99M |
Cash Only | 340.68M | 58.86M | 57.23M | 160.02M | 123.41M | 523.51M | 226.75M | 189.18M | 155.46M | 134.7M |
Short-Term Investments | 0 | 255.2M | 222.5M | 437.35M | 625.28M | 669.12M | 685.48M | 412.33M | 294.42M | 241.29M |
Accounts Receivable | 10.47M | 7.55M | 4.62M | 2.13M | 2.03M | 3.77M | 36.46M | 8.52M | 9.47M | 9.13M |
Days Sales Outstanding | 146.34 | 90.51 | 39.12 | 13.41 | 22.43 | 26.39 | 366.82 | 53.71 | 51.07 | 56.61 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 3.68M | 3.37M | 0 | 0 | 0 | 20.41M | 49.65M | 29.83M | 68.36M | 81.33M |
Total Non-Current Assets | 21.41M | 22.34M | 44.8M | 59.8M | 525.16M | 303.32M | 302.65M | 551.15M | 314.42M | 292.33M |
Property, Plant & Equipment | 15.27M | 17.06M | 37.13M | 55.06M | 100.11M | 161M | 148.13M | 246.67M | 123.63M | 113.06M |
Fixed Asset Turnover | 1.71x | 1.78x | 1.16x | 1.05x | 0.33x | 0.32x | 0.24x | 0.23x | 0.55x | 0.47x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 4.75M | 4.75M | 425.05M | 142.32M | 154.51M | 44.26M | 35.54M | 458.83M |
Other Non-Current Assets | 6.13M | 5.28M | 2.92M | 0 | 0 | 0 | 0 | 260.21M | 155.25M | 141.26M |
Total Assets | 376.24M▲ 0% | 347.31M▼ 7.7% | 334.28M▼ 3.8% | 676.32M▲ 102.3% | 1.29B▲ 91.4% | 1.52B▲ 17.4% | 1.3B▼ 14.4% | 1.19B▼ 8.5% | 842.13M▼ 29.3% | 758.78M▲ 0% |
Asset Turnover | 0.07x | 0.09x | 0.13x | 0.09x | 0.03x | 0.03x | 0.03x | 0.05x | 0.08x | 0.08x |
Asset Growth % | 25.84% | -7.69% | -3.75% | 102.32% | 91.4% | 17.43% | -14.42% | -8.45% | -29.29% | -98.05% |
Total Current Liabilities | 31.36M | 40.57M | 35.63M | 64.25M | 125.83M | 126.55M | 115.21M | 110.85M | 103.88M | 76.44M |
Accounts Payable | 2.17M | 2.71M | 3.94M | 10.46M | 9.65M | 5.15M | 7.45M | 14.59M | 20.25M | 18.8M |
Days Payables Outstanding | 11.72 | 11.09 | 13.27 | 25.38 | 511.3 | 248.44 | 303.03 | 517.74 | 464.23 | 65.02 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.48M | 19.09M |
Deferred Revenue (Current) | 21.19M | 27.12M | 12.67M | 22.54M | 63.76M | 43.84M | 22.14M | 20.66M | 7.29M | 25.07M |
Other Current Liabilities | 3.23M | 4.57M | 6.31M | 10.92M | 20.36M | 21.78M | 6.89M | 55.35M | 49.86M | 37.92M |
Current Ratio | 11.32x | 8.01x | 8.12x | 9.59x | 6.11x | 9.61x | 8.67x | 5.77x | 5.08x | 6.10x |
Quick Ratio | 11.32x | 8.01x | 8.12x | 9.59x | 6.11x | 9.61x | 8.67x | 5.77x | 5.08x | 6.10x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -8.41 |
Total Non-Current Liabilities | 44.28M | 28.82M | 28.77M | 85M | 128.39M | 157.98M | 135.6M | 208.21M | 66.85M | 61.4M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.85M | 61.4M |
Capital Lease Obligations | 0 | 0 | 12.63M | 33.61M | 64.91M | 114.02M | 96.75M | 189.95M | 0 | 146.19M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -38.85M | 0 | 0 | 0 |
Other Non-Current Liabilities | 168K | 13K | 0 | 0 | 0 | 24.03M | 38.85M | 0 | 0 | 0 |
Total Liabilities | 75.64M | 69.39M | 64.4M | 149.25M | 254.22M | 284.53M | 250.81M | 319.06M | 170.73M | 137.84M |
Total Debt | 0 | 0 | 18.38M | 39.3M | 74.02M | 130.7M | 115.35M | 210.2M | 93.33M | 80.49M |
Net Debt | -340.68M | -58.86M | -38.85M | -120.72M | -49.38M | -392.8M | -111.4M | 21.02M | -62.13M | -54.21M |
Debt / Equity | - | - | 0.07x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x | 0.14x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.20x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.13x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 300.6M▲ 0% | 277.92M▼ 7.5% | 269.88M▼ 2.9% | 527.07M▲ 95.3% | 1.04B▲ 97.4% | 1.24B▲ 18.8% | 1.05B▼ 15.0% | 871.96M▼ 17.0% | 671.39M▼ 23.0% | 620.94M▲ 0% |
Equity Growth % | 43.25% | -7.54% | -2.89% | 95.3% | 97.36% | 18.78% | -15.01% | -16.97% | -23% | -91.98% |
Book Value per Share | 8.35 | 6.45 | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.82 | 6.20 | 5.24 |
Total Shareholders' Equity | 300.6M | 277.92M | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B | 871.96M | 671.39M | 620.94M |
Common Stock | 4K | 5K | 5K | 7K | 7K | 9K | 9K | 10K | 12K | 12K |
Retained Earnings | -121.11M | -201.03M | -300.88M | -435.11M | -703M | -1.18B | -1.66B | -2.18B | -2.59B | -2.69B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -28K | 261K | 1K | -2.63M | -7.46M | -2.26M | 605K | 1.03M | -240K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NTLA Cash Flow Statement
Intellia Therapeutics, Inc. (NTLA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -65.28M | -61.26M | -103.24M | -49.91M | -225.03M | -333.29M | -394.09M | -348.88M | -348.88M | -363.15M |
Operating CF Margin % | -249.94% | -201.28% | -239.52% | -86.06% | -680.82% | -639.45% | -1086.38% | -602.8% | -515.55% | - |
Operating CF Growth % | -280.77% | 6.16% | -68.54% | 51.65% | -350.85% | -48.11% | -18.24% | 11.47% | 0% | -21.97% |
Net Income | -67.54M | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -519.02M | -394.6M |
Depreciation & Amortization | 2.99M | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M | 10.29M | 9.99M |
Stock-Based Compensation | 15.32M | 17.05M | 15.09M | 19.9M | 47.01M | 91.4M | 134.05M | 154.27M | 154.27M | 132.43M |
Deferred Taxes | 0 | 0 | 0 | 0 | 8.93M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 166K | -601K | -3.72M | 573K | 2.94M | 95.8M | -3.47M | -6.29M | 79.33M | 47.48M |
Working Capital Changes | -16.21M | 3.18M | -20.66M | 57.53M | -22.9M | -53.87M | -52.45M | 11.88M | -73.75M | -52.13M |
Change in Receivables | -4.02M | 2.92M | 2.93M | 2.49M | 99K | -1.74M | -32.69M | 27.94M | -951K | 1.37M |
Change in Inventory | 1.28M | 3.96M | 1.65M | 0 | 7.82M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -488K | 232K | 1.88M | 5.06M | 529K | -4.58M | 2.52M | 6.8M | 5.99M | 6.44M |
Cash from Investing | -10.09M | -260.78M | 25.18M | -214.49M | -550.78M | 160.31M | -31.35M | 125.57M | 125.57M | 200.01M |
Capital Expenditures | -10.09M | -6.36M | -6.79M | -3.58M | -12.76M | -58.39M | -13.98M | -5.78M | -5.78M | -5.12M |
CapEx % of Revenue | 38.64% | 20.89% | 15.76% | 6.18% | 38.59% | 112.03% | 38.55% | 9.98% | 8.54% | 7.75% |
Acquisitions | 0 | 131K | -31.97M | 0 | -3M | -44.68M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -10.1K | 131K | 31.97M | 0 | 0 | 44.83M | 0 | 0 | 20.97M | 123.43M |
Cash from Financing | 142.98M | 40.22M | 76.43M | 371.78M | 736.69M | 582.96M | 130.32M | 185.75M | 185.75M | 165.06M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 141M | 28.55M | 72.26M | 358.65M | 693.57M | 565.79M | 119.8M | 176.9M | 131.49M | 130.15M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.98M | 11.67M | 4.18M | 13.13M | 43.12M | 17.17M | 10.53M | 8.85M | 54.26M | 34.9M |
Net Change in Cash | 67.61M▲ 0% | -281.82M▼ 516.8% | -1.63M▲ 99.4% | 107.38M▲ 6687.7% | -39.12M▼ 136.4% | 409.98M▲ 1148.0% | -295.11M▼ 172.0% | -37.57M▲ 87.3% | -37.57M▲ 0.0% | 465K▲ 0% |
Free Cash Flow | -75.37M▲ 0% | -67.61M▲ 10.3% | -110.03M▼ 62.7% | -53.5M▲ 51.4% | -237.79M▼ 344.5% | -391.68M▼ 64.7% | -408.07M▼ 4.2% | -354.66M▲ 13.1% | -354.66M▲ 0.0% | -363.63M▲ 0% |
FCF Margin % | -288.57% | -222.17% | -255.28% | -92.25% | -719.41% | -751.48% | -1124.94% | -612.78% | -524.09% | -550.18% |
FCF Growth % | -351.69% | 10.29% | -62.74% | 51.38% | -344.48% | -64.72% | -4.19% | 13.09% | 0% | 4.6% |
FCF per Share | -2.09 | -1.57 | -2.33 | -0.96 | -3.35 | -5.09 | -4.60 | -3.59 | -3.27 | -3.07 |
FCF Conversion (FCF/Net Income) | 0.97x | 0.72x | 1.04x | 0.37x | 0.84x | 0.70x | 0.82x | 0.67x | 0.85x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NTLA Key Ratios
Intellia Therapeutics, Inc. (NTLA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -26.46% | -29.5% | -36.34% | -33.69% | -34.18% | -41.67% | -42.1% | -54% | -53.48% | -57.27% |
Return on Invested Capital (ROIC) | - | -76.16% | -35.45% | -32.14% | -28.76% | -37.48% | -43.39% | -43.75% | -44.03% | -50.68% |
Gross Margin | -159.02% | -192.81% | -151.52% | -159.35% | 79.15% | 85.47% | 75.26% | 82.23% | 76.47% | -31.89% |
Net Margin | -258.62% | -280.42% | -230.92% | -231.46% | -810.49% | -909.78% | -1326.51% | -896.77% | -609.85% | -597.04% |
Debt / Equity | - | - | 0.07x | 0.07x | 0.07x | 0.11x | 0.11x | 0.24x | 0.14x | 0.13x |
FCF Conversion | 0.97x | 0.72x | 1.04x | 0.37x | 0.84x | 0.70x | 0.82x | 0.67x | 0.85x | 0.92x |
Revenue Growth | 58.49% | 16.53% | 41.63% | 34.55% | -43.01% | 57.69% | -30.4% | 59.55% | 16.92% | 45.04% |
Related:NTLA Dividend History·NTLA Revenue History·NTLA Price History·NTLA P/E History·NTLA Financial Ratios·NTLA Institutional Holders
NTLA SEC Filings & Documents
Intellia Therapeutics, Inc. (NTLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
NTLA Frequently Asked Questions
Intellia Therapeutics, Inc. (NTLA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Intellia Therapeutics, Inc. (NTLA) reported $66.1M in revenue for fiscal year 2025.
Intellia Therapeutics, Inc. (NTLA) grew revenue by 16.9% over the past year. This is strong growth.
Intellia Therapeutics, Inc. (NTLA) reported a net loss of $394.6M for fiscal year 2025.
Dividend & Returns
Intellia Therapeutics, Inc. (NTLA) has a return on equity (ROE) of -53.5%. Negative ROE indicates the company is unprofitable.
Intellia Therapeutics, Inc. (NTLA) had negative free cash flow of $363.6M in fiscal year 2025, likely due to heavy capital investments.